Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24 USD | +4.17% | -2.00% | +73.41% |
May. 14 | Enliven Therapeutics Q1 Loss Narrows | MT |
Apr. 11 | Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.41% | 1.08B | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics Q3 Loss Narrows